共 6 条
[1]
Clinical features; pathogenesis; and treatment of Guillain-Barré syndrome.[J].Pieter A van Doorn;Liselotte Ruts;Bart C Jacobs.Lancet Neurology.2008, 10
[3]
Does Campylobacter jejuni infection elicit “demyelinating” Guillain–Barré syndrome?.[J].S Kuwabara;K Ogawara;S Misawa;M Koga;M Mori;A Hiraga;T Kanesaka;T Hattori;N Yuki.Neurology.2004, 3
[5]
Practice parameter: Immunotherapy for Guillain–Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology.[J].R.A.C. Hughes;E.F.M. Wijdicks;R. Barohn;E. Benson;D.R. Cornblath;A. F. Hahn;J.M. Meythaler;R.G. Miller;J.T. Sladky;J.C. Stevens.Neurology.2003, 6
[6]
Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes.[J].A. Hiraga;M. Mori;K. Ogawara;T. Hattori;S. Kuwabara.Neurology.2003, 4

